SPRY vs UHS
SPRY: Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment. UHS: Large diversified hospital operator running 375 acute care and behavioral health inpatient facilities across the US, UK, and Puerto Rico, with 42% of revenues from behavioral health services.
Side-by-side fundamentals
| Metric | SPRY | UHS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.06 | $149.34 | |
| Market cap as of 2026-07-23 | $602M | $9.1B | |
| P/E as of 2026-07-23 | n/a | 5.95 | |
| PEG as of 2026-07-23 | -0.00 | 0.63 | SPRY lower |
| Net margin as of 2026-07-23 | -200.0% | +8.6% | UHS higher |
| Gross margin as of 2026-07-23 | +74.1% | n/a | |
| Operating margin as of 2026-07-23 | -204.5% | +11.5% | UHS higher |
| ROE as of 2026-07-23 | -153.6% | +21.0% | UHS higher |
| ROA as of 2026-07-23 | -60.9% | +9.9% | UHS higher |
| Debt / equity as of 2026-07-23 | 1.57 | 0.63 | UHS lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | +10.4% | UHS higher |
| Revenue CAGR (3y) SEC XBRL | +300.1% | +9.0% | SPRY higher |
| Dividend yield as of 2026-07-23 | n/a | +0.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.02 | 1.08 | |
| 1-year return as of 2026-07-22 close | -64.4% | -8.2% | UHS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.